Depression involves a wide range of emotional, cognitive, and physical symptoms that disrupt daily life. Societal changes such as technological advances, economic pressures, climate change, and shifting cultural norms have altered how depression appears and is understood, leading to the identification of new depression subtypes. These include depression in adolescents and young adults, depression with social disconnection, depression with alcohol or substance use disorder, depression with gender dysphoria, and depression linked to stressful events and environmental factors. Managing these subtypes requires individualized treatment approaches. While SSRIs and SNRIs remain standard, atypical antidepressants like trazodone, ketamine, neuromodulation, and personalized psychotherapy offer hope for complex or treatment-resistant cases.
Major depressive disorder (MDD) is a major health issue in adolescents and young adults, causing high disability and impairing functioning. Its clinical presentation can differ from that in adults, and standard antidepressant treatments often yield suboptimal responses. About 40% of youths with MDD experience treatment-resistant depression (TRD), which is linked to higher rates of comorbid conditions and suicidality. Various biological, environmental, and clinical factors contribute to TRD, which may also signal an unrecognized bipolar disorder, complicating diagnosis. This review summarizes evidence on TRD's epidemiology and clinical features in this age group and discusses possible treatments, including novel fast-acting antidepressants. These drugs show promise but require careful risk-benefit assessment within integrated care models.